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INTRODUCTION 
Among different strategies that can be used for enhancing 
the dissolution rate of poorly soluble drugs, particle size 
reduction proved to give interesting results. Processes 
able to reduce the size of drug particles to the sub-micron 
range (typically 100-200 nm) allow a significant increase 
of the dissolution rate that could mean an ameliorated 
bioavailability. High pressure homogenization (HPH) has 
been successfully used for the production nanoparticles 
characterized by reproducible particle sizes and capable 
of generate stable nanosuspensions [1]. 
Pellets are interesting pharmaceutical innovative 
formulations that combine a high flexibility in the dosage 
form development and a significant improvement in 
terms of safety [2]. They are less susceptible to the 
variations in the gastric empty times thus minimizing 
intra- and inter-subject variability of plasma profiles. 
Pellets can also be employed for the preparation of fast 
release systems by layering the drug on the surface of 
inert cores for promoting the dissolution rate. 
Even if nanotechnologies are a promising tool for the 
development of novel drug delivery systems with a 
variety of applications, the biggest challenge consists in 
the formulation of nanosized material in dosage forms 
that do not compromise their release performances. 
The aims of the present work were i) to prepare a stable 
nanosuspension of a poorly soluble drug; ii) to obtain a 
versatile form of the nanonized drug that can be easily re-
dispersed and handled; iii) to explore the possibility of 
producing fast disintegrating pellets by 
extrusion/spheronization loading a nanonized drug 
without compromising its dissolution performances. 
Itraconazole (ITZ), an antifungal agent, characterized by 
a very low aqueous solubility, a poor oral bioavailability 
and high inter-individual variations in the plasma drug 
concentrations was chosen as the model drug. 
 
EXPERIMENTAL METHODS 
Nanonizing process 
Nanosuspensions were prepared by a high-pressure 
homogenizer (HPH, Microfluidizer M-110L, 
Microfluidics, MA, USA). Preliminary trials, carried out 
using several stabilizing agents and surfactants in various 
amounts (0.5 to 2.0% w/w), and different homogenization 
conditions (pressure 3,000-18,000 psi, temperature 4-
25°C, reprocessing times 10-40 minutes) allowed to 
identify the optimal setting of the nanonizing process. 
The obtained nanosuspension was subjected to spray 
drying carried out using a Spray-dryer (Mod. B-290, 
Buchi Labortechnick AG, CH) operating at 150°C (inlet 
temperature) with an air flux of 60 L/h at a spray rate of 
15 mL/min. 
Particle size analysis 
The solid nanonized products were analysed by Zetasizer 
3000HS (Malvern, UK) to determine the particle size. As 
a reference, micronized ITZ (as received by the 
manufacturer) was also analysed by a Mastersizer 2000 
(Malvern, UK). 
Pelletization process 
Pellets containing 22% w/w ITZ were prepared by 
extrusion-spheronization. Different functional 
pelletization excipients were evaluated in order to prepare 
disintegrating pellets with acceptable sphericity. The final 
excipients composition of pellets selected for this study 
was Avicel PH101 33%, Kollidon CL 33% and Methocel 
E5 33% w/w. The excipients were granulated in mortar 
by adding the nanonized dry powder (ITZnanoDP) to the 
excipients mixture and wetted with water. Alternatively 
the wet masses were prepared introducing ITZ nanonized 
dry powder redispersed in water by 3 min sonication 
(ITZnanoLD) and used as the wetting liquid. Pellets 
containing micronized ITZ were also prepared by using 
the analogous procedures (ITZmicroDP and 
ITZmicroLD). When employing micronized ITZ, Tween 
20 was added to the wetting solution for replicating the 
composition of nanonized systems (0.84% w/w based on 
the pellet composition). The wet masses were extruded 
using a radial screen extruder (Nica E4, GEA, B; screen 
size 1.0 mm). The extrudates were fed into the 
spheronizer (Nica S2-450, GEA, B) that operated at 700 
rpm for 5 min. The wet pellets were dried in static oven at 
40°C for 12 h (moisture content <5%).  
Release study 
Release tests were performed on powders and pellets in 
USP dissolution apparatus 2 (AT7, Sotax, CH; 100 rpm, 
37.0±0.5°C, n=6) in SGF without enzymes (USP). 
Samples were withdrawn at fixed time points and 
spectrophotometrically assayed for the drug content. 
RESULTS AND DISCUSSION 
The results of preliminary tests conducted on 
nanosuspensions prepared with various surfactants (SLS, 
Tween 20 and 60, Span 20 and 80, Cremophor ELP) and 
different suspending polymers (HPMC, poloxamer 407, 
Lutrol F127, CMC, HEC) led to identify the most 
promising formulation and most effective set of HPH 
conditions. A nanonized ITZ dispersion, characterized by 
acceptably small particles size and good physical stability 
was obtained starting from micronized ITZ (25% w/w) in 
water added of Tween 20 (1% w/w) using HPH at 18000 
psi for 40 minutes operating at 4°C. The nanonizing 
process produced particles with a mean diameter of 456 
nm, about 20 times lower than that of the starting 
micronized material (mean diameter 8.9 m) (Fig. 1). The 
nanosuspension was spray dried for enabling an easy 
handling and for increasing the formulation possibilities 
of the drug. The dried powder was dispersed in water by 
sonication for 3 min and a stable nanosuspension was 
obtained. The particle size of the original nanosuspension 
was only slightly affected by the drying and dispersing 
processes (mean diameter 677 nm). 
 
Figure 1: Particle size distribution of nanonized ITZ before 
(blue) and after (green) spray drying and 
micronized (red) itraconazole powder. 
 
The results obtained from the dissolution tests, carried out 
on nanonized and micronized ITZ dry powders 
(ITZnanoDP and ITZmicroDP respectively), indicated 
that the reduction of the particle size increased the 
dissolution rate: in particular, an evident increase has 
been observed when the dried powder of nanonized ITZ 
was redispersed in water (5 mg/mL) (ITZnanoLD) before 
the test (Fig. 2). 
The pellet composition was set up employing micronized 
and nanonized ITZ using Kollidon CL as disintegrating 
agent, Methocel E5 as hydrophylic binder and Avicel 
PH101 as spheronizing aid. In Fig. 3, the release profiles 
of ITZ from the pellets are reported. The release profiles 
from pellets containing nanonized or micronized ITZ 
were significantly different (f2 values range between 34 
and 40). The pellets ITZnanoLD gave the highest release 
rate: after 30 minutes, the pellets formulated with 
ITZnano released 58.7% of ITZ, while only 40.8% of 
drug was released from pellets prepared with ITZmicro. 
At the end of the test (120 min), the pellets containing 
nanonized ITZ released 72.6% drug compared to 53.2% 
with pellets prepared with micronized ITZ. 
 
Figure 2:  Dissolution profiles of ITZ powders with 
different particle sizes and ITZ nanonized dry 
powder re-dispersed in water (5 mg/mL). 
Comparing the pellets prepared with the drug as powder 
with those obtained using ITZ re-suspended in water, the 
release profiles resulted not substantially different (f2 
parameter value 65.5 for pellets ITZnanoLD vs. pellets 
ITZnanoDP and 69.6 for pellets ITZmicroLD vs. pellets 
ITZmicroDP). 
 
Figure 3: Dissolution profiles obtained from pellets 
prepared with ITZmicro and ITZnano dry 
powders (DP) or liquid dispersion (LD). 
CONCLUSIONS 
The study demonstrated that HPH is effective in the 
particle size reduction: the nanonization of a poorly 
soluble drug such as ITZ in the presence of a surface 
active agent increased its dissolution rate. Fast 
disintegrating pellets were obtained by 
extrusion/spheronization with the nanonized ITZ, and 
ameliorated release performances were observed in 
comparison with systems containing the drug as 
micronized powder.  
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